超极化丙酮酸MR波谱可显示胶质瘤小鼠模型中的糖酵解抑制
该动物研究在7T下对原位U87MG胶质瘤小鼠和健康对照小鼠静脉注射超极化[1-13C]-丙酮酸后行动态13C MR波谱,评估糖酵解抑制剂WP1122治疗前后乳酸生成变化;胶质瘤小鼠治疗后乳酸生成速率kPL和归一化乳酸比nLac均下降(P=.01),健康对照无显著下降。
要点
- 超极化[1-13C]-丙酮酸MR波谱可在活体实时定量胶质瘤糖酵解产物乳酸。
- 胶质瘤小鼠接受WP1122后kPL由0.027降至0.018 sec-1(P=.01),nLac由0.28降至0.22(P=.01)。
- 健康对照小鼠治疗前后kPL和nLac均无显著下降(P=.91和P=.84)。
核心结论
- 超极化碳13测量丙酮酸代谢可为监测胶质瘤治疗反应提供快速反馈。
研究设计与样本
- 动物研究,13只12-16周龄雌性原位U87MG胶质瘤小鼠和5只健康雌性小鼠,在7T下行解剖MRI和动态13C MR波谱,于静脉注射超极化[1-13C]-丙酮酸时采集,并在给予糖酵解抑制剂WP1122(2-脱氧-d-葡萄糖的前药)后重复;实验于2016年10月至2017年3月在无胸腺裸鼠中进行;采用Wilcoxon符号秩检验评估配对乳酸生成指标变化。
关键影像表现/征象
- 胶质瘤小鼠在植入后第40天T2加权和T1加权增强MRI上显示大的对比剂强化肿瘤。
- 超极化乳酸生成以表观反应速率kPL和归一化乳酸比nLac定量。
诊断标准与关键数值
- 胶质瘤小鼠基线及治疗后平均kPL分别为0.027和0.018 sec-1(P=.01)。
- 胶质瘤小鼠基线及治疗后平均nLac分别为0.28和0.22(P=.01)。
- 健康对照小鼠基线及治疗后平均kPL分别为0.011和0.017 sec-1(P=.91)。
- 健康对照小鼠基线及治疗后平均nLac分别为0.16和0.21(P=.84)。
临床应用与阅片要点
- 作者认为超极化碳13丙酮酸代谢测量可为监测胶质瘤治疗反应提供快速反馈。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BackgroundA generation of therapies targeting tumor metabolism is becoming available for treating glioma. Hyperpolarized MRI is uniquely suited to directly measure the metabolic effects of these emerging treatments.PurposeTo explore the feasibility of the use of hyperpolarized [1-carbon 13 {13C}]-pyruvate for real-time measurement of metabolism and response to treatment with a glycolytic inhibitor in an orthotopic mouse model of glioma.Materials and MethodsIn this animal study, anatomic MRI and dynamic 13C MR spectroscopy were performed at 7 T during intravenous injection of hyperpolarized [1-13C]-pyruvate on mice with orthotopic U87MG glioma and healthy control mice. Anatomic MRI and dynamic 13C MR spectroscopy were repeated after administration of the glycolytic inhibitor WP1122, a prodrug of 2-deoxy-d-glucose. All experiments were conducted in athymic nude mice between October 2016 and March 2017. Hyperpolarized lactate production was quantified as an apparent reaction rate, or kPL, and normalized lactate ratio (nLac). The Wilcoxon signed-rank test was used to assess changes in paired measures of lactate production before and after treatment.ResultsThirteen 12-16-week-old female mice and five healthy female mice underwent anatomic MRI and hyperpolarized [1-13C]-pyruvate spectroscopy. Large contrast agent-enhanced tumors were shown in mice with glioma at T2-weighted and T1-weighted postcontrast MRI by postimplantation day 40. After treatment with WP1122, a decrease in lactate was observed in mice with glioma (baseline and treatment mean kPL, 0.027 and 0.018 sec-1, respectively, P = .01; baseline and posttreatment mean nLac, 0.28 and 0.22, respectively, P = .01) whereas no significant decrease was observed in healthy control mice (baseline and posttreatment mean kPL, 0.011 and 0.017 sec-1, respectively, P = .91; baseline and posttreatment mean nLac, 0.16 and 0.21, respectively, P = .84).ConclusionHyperpolarized carbon 13 measurements of pyruvate metabolism can provide rapid feedback for monitoring treatment response in glioma.© RSNA, 2019.
引用
- Michel KA, Zieliński R, Walker CM, et al. Hyperpolarized Pyruvate MR Spectroscopy Depicts Glycolytic Inhibition in a Mouse Model of Glioma. Radiology. 2019. PMID: 31385757. doi:10.1148/radiol.2019182919
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。